LCA5

1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Opus Genetics
Opus GeneticsNC - Raleigh
1 program
1
AAV8.hLCA5Phase 1/21 trial
Active Trials
NCT05616793RecruitingEst. Jun 2028

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
2028
Opus GeneticsAAV8.hLCA5

Clinical Trials (1)

Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients

Start: Jun 2023Est. completion: Jun 2028
Phase 1/2Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials
1 companies competing in this space